Evening Briefing Europe

Takeover Saga for Obesity Drugmaker Metsera Heats Up

Get caught up.

Novo Nordisk A/S Ozempic brand semaglutide medication.

Photographer: George Frey/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Caroline Alexander

November 4, 2025 at 5:00 PM UTC

The takeover saga for obesity drugmaker Metsera isn’t over yet.

Both Pfizer, which has been trying to enter the market for years without success, and Novo Nordisk, which is seeking to regain ground lost to Eli Lilly, boosted their bids for the US startup ahead of a court battle set for later today in Delaware.